Skip to Content
Merck
  • Long-term naringin consumption reverses a glucose uptake defect and improves cognitive deficits in a mouse model of Alzheimer's disease.

Long-term naringin consumption reverses a glucose uptake defect and improves cognitive deficits in a mouse model of Alzheimer's disease.

Pharmacology, biochemistry, and behavior (2012-06-29)
Dongmei Wang, Kai Gao, Xiaoying Li, Xinhua Shen, Xu Zhang, Chunmei Ma, Chuan Qin, Lianfeng Zhang
ABSTRACT

Naringin, a bioflavonoid, has been reported to have potent neuro-protective effects, but its preventive effects on amyloid-β (Aβ) induced, Alzheimer's disease (AD) related, cognitive impairment, and the underlying mechanisms of these effects have not been well characterised. Three-month-old APPswe/PSΔE9 transgenic mice were randomly assigned to a vehicle group, two naringin (either 50 or 100 mg/kg/day) groups, or an Aricept (2 mg/kg/day) group. After 16 weeks of treatment, we observed beneficial effects of naringin (100 mg/kg/day), including lessening learning and memory deficits, improving locomotor activity, reducing scattered senile plaques, and ameliorating disturbances in brain energy metabolism. Furthermore, GSK-3β phosphorylation significantly increased in the naringin-treated (100 mg/kg/day) group. These findings suggest that a reduction in plaque burden and an increase in glucose uptake through the inhibition of GSK-3β activity may be one of the mechanisms by which naringin improves cognitive functioning in the APPswe/ PSΔE9 transgenic mouse model of Alzheimer's disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Naringin, ≥90% (HPLC), from citrus fruit